nabumetone has been researched along with Kidney Failure, Chronic in 1 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Excerpt | Relevance | Reference |
---|---|---|
" We used a noncompartmental pharmacokinetic analysis and compared those results to a population pharmacokinetic analysis performed with nonlinear mixed-effects modeling (NONMEM)." | 1.29 | Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. ( Aronoff, GR; Brier, ME; Sloan, RS, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Brier, ME | 1 |
Sloan, RS | 1 |
Aronoff, GR | 1 |
1 other study available for nabumetone and Kidney Failure, Chronic
Article | Year |
---|---|
Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction.
Topics: Administration, Oral; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Half | 1995 |